This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Finerenone for treating chronic kidney disease in type 2 diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Finerenone for treating chronic kidney disease in type 2 diabetes

NICE guidance states:

  • finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults
    • is recommended only if:
      • it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
        • angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
        • sodium–glucose cotransporter-2 (SGLT2) inhibitors and
      • the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more

  • the NICE committee stated:
    • standard care for chronic kidney disease in people with type 2 diabetes includes ACE inhibitors and ARBs, with SGLT2 inhibitors being added if needed
      • finerenone would be added to ACE inhibitors and ARBs if they are not working well enough
        • could be offered before, after, or with SGLT2 inhibitors
      • clinical evidence suggests that finerenone improves kidney function and helps to slow the worsening of the disease compared with placebo (both plus standard care, with and without SGLT2 inhibitors)
      • are no direct comparisons of finerenone against SGLT2 inhibitors when used as an add-on to standard care (without SGLT2 inhibitors)

  • evidence shows that patients with T2DM and CKD, who received finerenone had a significant lower risk of a primary kidney event compared to patients treated with placebo (2)
    • also a composite of CV events was reduced by finerenone in these patients when compared to placebo


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.